Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Harvard Business School
UBS
Merck
Fuji
Deloitte
Boehringer Ingelheim
Fish and Richardson
Chinese Patent Office

Generated: October 20, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022250

« Back to Dashboard

NDA 022250 describes AMPYRA, which is a drug marketed by Acorda and is included in one NDA. It is available from two suppliers. There are six patents protecting this drug and one Paragraph IV challenge. Additional details are available on the AMPYRA profile page.

The generic ingredient in AMPYRA is dalfampridine. There are ten drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the dalfampridine profile page.
Summary for 022250
Tradename:AMPYRA
Applicant:Acorda
Ingredient:dalfampridine
Patents:6
Formulation / Manufacturing:see details
Pharmacology for NDA: 022250
Mechanism of ActionPotassium Channel Antagonists
Suppliers and Packaging for NDA: 022250
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
AMPYRA dalfampridine TABLET, EXTENDED RELEASE;ORAL 022250 NDA AUTHORIZED GENERIC Mylan Pharmaceuticals Inc. 0378-0509 0378-0509-91 60 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (0378-0509-91)
AMPYRA dalfampridine TABLET, EXTENDED RELEASE;ORAL 022250 NDA Acorda Therapeutics, Inc. 10144-427 10144-427-60 60 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (10144-427-60)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrength10MG
Approval Date:Jan 22, 2010TE:ABRLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:Jul 30, 2018Product Flag?Substance Flag?Delist Request?
Patented Use:IMPROVEMENT OF WALKING IN PATIENTS WITH MULTIPLE SCLEROSIS (MS)
Patent:➤ Try a Free TrialPatent Expiration:May 26, 2027Product Flag?Substance Flag?Delist Request?
Patented Use:IMPROVEMENT OF WALKING IN PATIENTS WITH MULTIPLE SCLEROSIS (MS)
Patent:➤ Try a Free TrialPatent Expiration:Dec 22, 2026Product Flag?Substance Flag?Delist Request?
Patented Use:IMPROVEMENT OF WALKING IN PATIENTS WITH MULTIPLE SCLEROSIS (MS)

Expired US Patents for NDA 022250

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Acorda AMPYRA dalfampridine TABLET, EXTENDED RELEASE;ORAL 022250-001 Jan 22, 2010 ➤ Try a Free Trial ➤ Try a Free Trial
Acorda AMPYRA dalfampridine TABLET, EXTENDED RELEASE;ORAL 022250-001 Jan 22, 2010 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Chubb
Julphar
Deloitte
Teva
Argus Health
Queensland Health
US Department of Justice
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.